Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 3/20 | 0.74 |
| ▸ | SELE | P16581 | 3/20 | 0.74 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.74 |
| ▸ | MPO | P05164 | 1/20 | 0.60 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.60 |
| ▸ | EDNRA | P25101 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040288 | 0.86 | ICAM1 (0.78) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL6940328 | 0.85 | ICAM1 (1.00) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL5034019 | 0.84 | ICAM1 (0.55) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL6945268 | 0.83 | ICAM1 (0.81) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL8443506 | 0.83 | ICAM1 (1.00) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL12553286 | 0.82 | ICAM1 (0.52) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL8442746 | 0.81 | ICAM1 (0.78) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL8442729 | 0.80 | ICAM1 (0.76) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL8445326 | 0.80 | ICAM1 (0.62) | ICAM1SELEVCAM1MPOCYSLTR1 | |
| SCHEMBL10374441 | 0.80 | ICAM1 (0.51) | ICAM1SELEVCAM1MPOCYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD (AU) | 2011-06-16 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7910770-B2 | 3-Isopropoxy-7-methoxy-N-(1H-1,2,3,4-tetrazol-5-yl)-1-benzo[b]thiophene-2-carboxamide; autoimmune diseases such as rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease | TRILLIUM THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| EP-1585745-A4 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | TRILLIUM THERAPEUTICS INC (CA) | 2008-07-09 | — | — | EP | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | TRILLIUM THERAPEUTICS, INC. (CA) | 2008-06-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| US-7332631-B2 | These compounds typically have a core lipophilic group, substituted with a group rich in pi -electrons, preferably having a delocalised pi -electron system; typically include at least one acidic group having a pi -electron system; Autoimmune diseases | TRILLIUM THERAPEUTICS INC. (CA) | 2008-02-19 | — | — | US | disclosed |
| EP-1585745-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | Arthron Limited (AU) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004058747-A1 | FC RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | ARTHRON LIMITED (AU) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144170-A1 | Fc RECEPTOR MODULATING COMPOUNDS AND COMPOSITIONS | FCGR1A, FCGR2A, FCGR3B | ICAM1 457/4885SELE 145/4885VCAM1 493/4885 |
| US-20080146632-A1 | Fc Receptor Modulating Compounds and Compositions | FCGR1A, FCGR2A, FCGR3B | ICAM1 457/4885SELE 145/4885VCAM1 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.